This is a repository copy of C9orf72 expansion differentially affects males with spinal onset amyotrophic lateral sclerosis.

White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/105834/

Version: Accepted Version

Article:

https://doi.org/10.1136/jnnp-2016-314093

Reuse
Unless indicated otherwise, fulltext items are protected by copyright with all rights reserved. The copyright exception in section 29 of the Copyright, Designs and Patents Act 1988 allows the making of a single copy solely for the purpose of non-commercial research or private study within the limits of fair dealing. The publisher or other rights-holder may allow further reproduction and re-use of this version - refer to the White Rose Research Online record for this item. Where records identify the publisher as the copyright holder, users can verify any specific terms of use on the publisher's website.

Takedown
If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.
C9orf72 expansion differentially affects males with spinal onset

Amyotrophic Lateral Sclerosis

Authors: James Rooney¹ MB BAO BCh, MSc ; Isabella Fogh² PhD; Henk-Jan Westeneng³ MD; Alice Vajda¹ PhD; Russell McLaughlin¹ PhD; Mark Heverin¹ MSc; Ashley Jones² PhD; Ruben van Eijk³ MD; Andrea Calvo⁴ MD, PhD; Letizia Mazzini⁵ MD; Christopher Shaw² MD, PhD; Karen Morrison⁶ DPhil, FRCP; Pamela J. Shaw MD, FRCP⁷; Wim Robberecht⁸ MD, PhD; Phillip Van Damme⁸,⁹ MD PhD; Ammar Al-Chalabi² PhD, FRCP; Leonard van den Berg³ MD, PhD; Adriano Chiò⁴ MD; Jan Veldink³ MD, PhD; Orla Hardiman¹,¹⁰ MD, FRCPI.

Affiliations:
1. Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College, Dublin, Ireland
2. Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, United Kingdom
3. Department of Neurology and Neurosurgery, Brain Center Rudolf Magnus, University Medical Center Utrecht, Utrecht, the Netherlands
4. Department of Neuroscience, ALS Centre, University of Torino, Turin, Italy
5. ALS Center, Department of Neurology, Azienda Ospedaliera Universitaria Maggiore della Carità, Novara, Italy
6. Institute of Clinical Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham UK
7. Sheffield Institute for Translational Neuroscience, University of Sheffield, UK
8. KU Leuven - University of Leuven, Department of Neurosciences, VIB - Vesalius Research Center, Experimental Neurology - Laboratory of Neurobiology, Leuven, Belgium
9. Department of Neurology, University Hospital Leuven, Leuven Belgium
10. Department of Neurology, Beaumont Hospital, Dublin, Ireland

Corresponding author: James Rooney, Academic Unit of Neurology, Trinity Biomedical Sciences Institute, Trinity College, Dublin, Ireland. Tel: + 353 (01) 8961509. Email: jrooney@rcsi.ie

Keywords: amyotrophic lateral sclerosis, ALS, C9orf72, survival, prognosis, genetic
Disclosures

James Rooney was funded by the Health Research Programme Clinical Fellowship Programme (grant n. HPF-2014-527). He reports no conflicts of interest. Isabella Fogh was supported by funds from Motor Neurone Disease Association of Great Britain and Northern Ireland (grant n.905-793, 6058). She reports no conflict of interest. Phillip Van Damme holds a senior clinical investigatorship of FWO-Vlaanderen and is supported by the Belgian ALS liga. Ammar Al-Chalabi is Chief Investigator of a clinical trial by OrionPharma, served on the scientific advisory board of the Motor Neurone Disease Association, is on the Editorial Board of the journals “F1000” and “Amyotrophic Lateral Sclerosis and Frontotemporal Dementia”, has consulted for GSK, OrionPharma, Biogen Inc, Cytokinetics, and Treeway, and receives royalties from the books “The Brain” (Oneworld Publications) and “The Genetics of Complex Human Diseases” (Cold Spring Harbor Laboratory Press). He has grants from the Motor Neurone Disease Association, ALS Association, National Institute for Health Research, European Commission, Medical Research Council and Economic and Social Research Council. Wim Robberecht is supported by the European Community’s Health Seventh Framework Programme (FP7/2007-2013) under grant agreement number 259867 and from the European Research Council and the European’s Seventh Framework Programme (FP7/2007-2013)/ ERC grant agreement n° 340429, by funding from the Opening the Future Fund, Hart voor ALS Fund and by the E. von Behring Chair for Neuromuscular and Neurodegenerative Disorders, all at the University of Leuven, and by funding from the ALS League Belgium, the Thierry Latran Foundation, and the Geneeskundige Stichting Koningin Elisabeth (G.S.K.E.).

Pamela Shaw is Principal Investigator of a clinical trial by OrionPharma, served on the scientific advisory board of the UK Medical Research Council, is on the Editorial Board of the “Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Journal”, has consulted for, OrionPhama, Biogen Inc, Cytokinetics, Treeway and Sanofi Aventis, and receives royalties from the books “Oxford Textbook of Neurology. He has grants from the Motor
Neurone Disease Association, National Institute for Health Research, European Commission, Medical Research Council and ALS Worldwide. She is supported as an NIHR Senior Investigator.

Adriano Chiò serves on the editorial advisory board of Amyotrophic Lateral Sclerosis and has received research support from the Italian Ministry of Health (Ricerca Finalizzata), Regione Piemonte (Ricerca Finalizzata), University of Turin, Fondazione Vialli e Mauro onlus, and the European Commission (Health Seventh Framework Programme); he has been a member of advisory panels Biogen Idec, Cytkinetics, Italfarmaco and Neuraltus.

Orla Hardiman is funded by the Health Research Board Clinician Scientist Programme. Prof. Hardiman has received speaking honoraria from Novartis, Biogen Idec, Sanofi Aventis and Merck-Serono. She has been a member of advisory panels for Biogen Idec, Allergan, Ono Pharmaceuticals, Novartis, Cytokinetics and Sanofi Aventis. She serves as Editor-in-Chief of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.

Leonard van den Berg received grants from the Netherlands Organization for Health Research and Development (Vici scheme), the Netherlands ALS Foundation, the European Community's Health Seventh Framework Programme (grant agreement no 259867), the SOPHIA project (funded through the EU Joint Programme – Neurodegenerative Disease Research, JPND), and travel grants and consultancy fees from Baxalta; serves on scientific advisory boards for Prinses Beatrix Spierfonds, Thierry Latran Foundation, Cytkinetics and Biogen. He serves on the editorial boards of ‘Amyotrophic Lateral Sclerosis and Frontotemporal Dementia’ and ‘Journal of Neurology, Neurosurgery and Psychiatry’.

Henk-Jan Westeneng, Russell McLaughlin, Alice Vajda, Mark Heverin, Ashley Jones, Ruben van Eijk and Jan Veldink report no disclosures and no conflicts of interest.

**Ethics Statement:**

Ethical approval for this study and data sharing was obtained at each participating centre, and data shared through a legal agreement under the auspices of the EU JPND STRENGTH consortium, administered through King's College London.
Abstract

Introduction:
The C9orf72 repeat expansion has been reported as a negative prognostic factor in amyotrophic lateral sclerosis (ALS). Here we have examined the prognostic impact of the C9orf72 repeat expansion in European subgroups based on gender and site of onset.

Methods:

C9orf72 status and demographic/clinical data from 4925 ALS patients drawn from three prospective ALS registers (Ireland, Italy and The Netherlands), and clinical datasets in the UK and Belgium. Flexible parametric survival models were built including known prognostic factors (age, diagnostic delay and site of onset), gender and the presence of an expanded repeat in C9orf72. These were used to explore the effects of C9orf72 on survival by gender and site of onset. Individual patient data (IPD) meta-analysis was used to estimate hazard ratios for results of particular importance.

Results:

457 (8.95%) of 4925 ALS cases carried the C9orf72 repeat expansion. A meta-analysis of C9orf72 estimated a survival hazard ratio (HR) of 1.36 (1.18 – 1.57) for those carrying the expansion. Models evaluating interaction between gender and C9orf72 repeat expansions demonstrated that the reduced survival due to C9orf72 expansion was being driven by spinal onset males (HR 1.56 (95% CI: 1.25 – 1.96).

Conclusions:

This study represents the largest combined analysis of the prognostic characteristics of the C9orf72 expansion. We have shown for this first time that the negative prognostic implication of this variant is driven by males with spinal onset disease, indicating a hitherto unrecognized gender-mediated effect of the variant that requires further exploration.
Introduction

Amyotrophic lateral sclerosis (ALS) is a debilitating disease with a poor prognosis. Progress towards developing new treatments has been limited both by disease heterogeneity, and by the likely interaction between genetic and environmental factors in disease pathogenesis. A pathological expansion of a hexanucleotide repeat in the C9orf72 gene accounts for up to 10% of those with ALS in populations of European extraction, and is associated with a distinctive clinical phenotype that includes fronto-temporal dementia in some instances. Although the C9orf72 repeat expansion has been shown to be an important negative prognostic factor in survival analyses, to date no study has been sufficiently large to permit robust analysis of interactions between the variant and demographic features including age, gender and site of onset. Here we used our combined clinical datasets to determine whether the presence of the expanded variant differentially modulates survival based on gender and site of onset.
Methods

Data sources /Case capture

Clinical data from ALS cases incident from January 2000 to April 2015 were collected from Belgium, Ireland, Italy, The Netherlands and the United Kingdom. All patients fulfilled the diagnostic criteria for ALS, and core data elements as defined by the ENCALS consortium were harmonised across data-sets for consistency based on existing consortia agreements. Due to the lack of an agreed international definition of 'familial ALS', and given a previous population based familial aggregation analysis from Ireland demonstrated a much higher familial ALS occurrence (16%) than usually recognised, we did not exclude cases based on family history. The Belgian and UK cases were collected from clinical research centre cohorts, while the Dutch, Irish and Italian cases were sourced from the prospective population based national registers.

In accordance with existing Consortia agreements, data were collated using the following variables: age of onset, date of onset, date of diagnosis, date of death / last known follow-up date, site of onset, revised El-Escorial diagnostic category (except Belgium), and \( C9orf72 \) status (normal or expanded). For all study participants, \( C9orf72 \) status was determined by repeat-primed PCR as described previously (with individual laboratory-based validation and quality control by Southern blot analyses).

Survival analysis strategy

Initially exploratory models were constructed using Cox proportional hazards regression to explore the effect of different time of entry to the studies. Cox models were generated including known important survival covariates including age of onset, site of onset, diagnostic delay and \( C9orf72 \). Cox models were compared using a likelihood ratio test, and by testing the validity of the proportional hazards assumption of each covariate at each timescale.
A base model using Royston-Parmar flexible parametric regression\textsuperscript{20} was built on the preferred timescale, with a proportional hazards scale and a number of degrees of freedom selected by comparison of the AIC (Akaike Information Criterion) and BIC (Bayesian Information Criterion) from models with increasing degrees of freedom, and the variance covariance matrix clustered by country. Survival follow-up was limited to 5 years from entry. Models were then built to explore the effect of \textit{C9orf72} status in sex and site of onset subgroups. The \textit{stpm2}\textsuperscript{21} and \textit{ipdmetan}\textsuperscript{22} commands from Stata MP 14.0 were used to perform the survival analysis and produce the meta-analysis graphs, whilst the \textit{ggplot2}\textsuperscript{23} package in R 3.1.1 was used to generate selected final graphs.
Ethics

Ethical approval for this study and data sharing was obtained at each participating centre, and data was shared through a legal agreement under the auspices of the EU JPND STRENGTH consortium, administered through King's College London and approved for combined analyses locally by each participating institution. For the purposes of this analysis, overarching approval was through the Irish Centre (Trinity College Dublin and Beaumont Hospital Research Ethics Committee (02/28 ; 05/49 ).
Results

Descriptive statistics and basic survival model

In total, 5,106 ALS cases met the inclusion criteria, of which 457 (8.95%) carried the \textit{C9orf72} repeat expansion. Breakdown of the demographics of the overall cohort by country is shown in table 1. Missing values were minimal affecting 181 cases (3.5%). Supplementary information 1 summarizes the basic survival model. An individual patient data (IPD) meta-analysis of \textit{C9orf72} status in the base model estimated a hazard ratio of 1.36 (1.18 – 1.57) for those carrying the expansion vs those not.

\textit{C9orf72}, gender and site of onset subgroup analysis

Survival curves were generated to evaluate the effect of \textit{C9orf72} status on gender and site of onset (Fig 1) which suggested three-way interaction. Therefore gender, site of onset and \textit{C9orf72} status were categorised into one variable with eight levels as demonstrated in Table 1. Through comparison of survival curves, redundant sub-groups were combined (Supplementary Information 2) leaving 3 groups: spinal onset males with the \textit{C9orf72} expansion, other spinal onset patients, and all bulbar onset patients. Survival curves for these groups showed that male spinal onset patients with the \textit{C9orf72} repeat expansion had a prognosis distinct from other spinal onset patients and similar to bulbar onset patients (Fig 2). Meta-analysis calculated a survival hazard ratio of 1.56 (95% CI: 1.25 – 1.96) for this group (figure 3). Adjustment for El Escorial category did not substantially alter the hazard ratio (1.57 CI:1.26 – 1.97). The finding was in the same direction in each country, although only the pooled estimate was statistically significant (figure 3).

The median ages and distribution of diagnostic delay across the final sub-groups is shown in Table 2. While age of onset was oldest in the bulbar onset group and youngest in the male spinal onset \textit{C9orf72} expanded group, the male spinal onset \textit{C9orf72} expanded group also had the highest
proportion in the “short” diagnostic delay category, consistent with the finding that the *C9orf72* expansion differentially affects disease course in a gender specific manner.

**Discussion**

Previously, studies have shown that people with ALS carrying a *C9orf72* repeat expansion in blood present at a younger age and have reduced survival when compared to patients without the expanded variant (Table 4). However, studies to date have not been sufficiently powered to determine whether the expanded variant differentially affects outcome in subgroups based on gender and site of onset. Our findings demonstrate an intriguing and previously unrecognized interaction between the expanded variant and male patients with spinal onset disease, which appears to drive the overall survival effect. Within this cohort, the median age of onset was 59.3 and the median survival was 2.29 years. This compared to a median age of onset of 62.3 and median survival of 2.77 yrs in all other spinal onset disease, and a median age of onset of 65 and median survival of 2.38 years in all bulbar onset disease. Moreover, and contrary to the usual pattern in young onset disease, male spinal onset *C9orf72* expanded cases were also more likely to have experienced a shorter diagnostic delay, suggesting rapidly progressing disease.

Gender has previously been reported as an independent predictor of functional decline in ALS\textsuperscript{24}, however our observation of an interaction between site of onset and gender has not been previously noted possibly due to limitations in the power of previous studies due to lower numbers (Table 4). Taken together, our findings and those of previous studies imply that distinct processes may operate in differing subgroups of ALS even when a known genetic factor is present as the underlying cause, and demonstrate that male gender is likely to be an important interacting factor in the biology of C9orf72 related disease.
A number of pathogenic mechanisms have been proposed to explain the role of the C9orf72 repeat expansion in ALS. These include haplo-insufficiency, toxic RNA interfering with the function of RNA-binding proteins or other cellular factors, and the presence of toxic dipeptide repeat proteins through RAN translation\textsuperscript{25,26}. Recent work has pointed also towards C9orf72 induced pathology of nucleocytoplasmic transport processes\textsuperscript{26–29}. However, the pathobiology of the observed interaction between the C9orf72 variant and gender remains unclear, but it is congruent with observations in the SOD1 mouse model, in which transgenic mutant males have shorter survival compared to their transgenic female littermates with similar copy numbers\textsuperscript{30}. The mechanism for this gender effect in animals, although well recognized has not been characterized, but can be attenuated when mice are bred on a different genetic background\textsuperscript{30}.

A potential weakness of our study is that it did not include clinical scores for the presence of cognitive change, which is a known prognostic indicator in ALS. We and others have shown that those with C9orf72 repeat expansions are more likely to experience cognitive and behavioural change, however to our knowledge to date, no gender mediated effect has been demonstrated in C9orf72 related cognitive profiling. Moreover, as C9orf72 is part of the causal pathway for some forms of FTD, inclusion of cognitive status as a variable would have introduced a selection bias based on ‘conditioning on a common effect’\textsuperscript{31}. A further limitation to this study is that our analysis does not include C9orf72 repeat expansion analysis by Southern blot, although Individual definition of pathological expansion performed by each centre using repeat primed PCR was validated by Southern blot. While the length of expansion varies from tissue to tissue\textsuperscript{32–34}, diagnostic testing within a clinical setting uses blood samples from which all previous prognostic and clinical correlative studies have been performed.

In conclusion, we have performed an analysis of the effect of the C9orf72 expansion on survival in almost 5000 European ALS patients. We have shown for the first time that C9orf72 repeat expansion is a significant negative prognostic indicator in males with spinal onset disease only.
These findings suggest a hitherto unrecognized interaction between the C9orf repeat expansion, site of onset and gender. This has important implications in understanding both the pathobiology of C9orf-mediated disease, and in the development of future disease-related prognostic models.

Acknowledgments

Belgium: This work was supported by the Interuniversity Attraction Poles (IUAP) program P7/16 of the Belgian Federal Science Policy Office, by the FWO-Vlaanderen under the frame of E-RARE-2, the ERA-Net for Research on Rare Diseases (PYRAMID) and by a EU Joint Programme - Neurodegenerative Disease Research (JPND) project (STRENGTH).

Ireland: The research leading to these results has received funding from the Health Research Board Interdisciplinary Capacity Enhancement Programme, the European Community's Seventh Framework Programme (FP7/2007-2013) under the Health Cooperation Programme and the project EUROMOTOR (No.259867).

Italy: This work was funded in part by Fondazione Vialli e Mauro per la Sclerosi Laterale Amiotrofica onlus, and Italian Ministry of Health (Ricerca Sanitaria Finalizzata, 2010, grant RF-2010-2309849.

Netherlands: This project was also supported by ZonMw, under the frame of E-Rare-2, the ERA-Net for Research on Rare Diseases” (PYRAMID), from the European Joint Programme in Neurodegeneration (SOPHIA and ALS-CarE) and the charity Research Motor Neurone.

UK: STRENGTH and ALS-CarE are EU Joint Programme - Neurodegenerative Disease Research (JPND) projects. The projects are supported through the following funding organisations under the aegis of JPND - www.jpnd.eu (United Kingdom, Medical Research Council and Economic and Social Research Council). CES and AAC receive salary support from the National Institute for Health Research (NIHR) Dementia Biomedical Research Unit at South London and Maudsley NHS Foundation Trust and King's College London. The work leading up to this publication was funded by the European Community’s Health Seventh Framework Programme (FP7/2007–2013; grant agreement number 259867). PJS is supported as an NIHR Senior Investigator. Samples used in this research were entirely/in part obtained from the UK National DNA Bank for MND Research, funded by the MND Association and the Wellcome Trust. We would like to thank people with MND and their families for their participation in this project. We acknowledge sample management undertaken by Biobanking Solutions funded by the Medical Research Council at the Centre for Integrated Genomic Medical Research, University of Manchester.

The funders played no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

Author contributions:

James Rooney had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: James Rooney, Isabella Fogh, Orla Hardiman
Acquisition of data: Henk-Jan Westeneng, Alice Vajda, Russell McLaughlin, Mark Heverin, Ashley Jones, Ruben can Eijk, Andrea Calvo, Letizia Mazzini, Christopher Shaw, Karen Morrison, Pamela J Shaw, Wim Robberecht, Phillip Van Damme, Ammar Al-Chalabi; Leonard van den Berg; Adriano Chiò; Jan Veldink; Orla Hardiman.

Statistical analysis: James Rooney; Henk-Jan Westeneng; Jan Veldink

Drafting of the manuscript: James Rooney, Orla Hardiman

Critical revision of the manuscript for important intellectual content: All authors.
References:


11 ENCALS. ALS Core Clinical Dataset. 2014

http://www.encals.eu/public/media/ac8bacd302965623601ddf4e229c4aadcc370922/6xg7/pdf/17a00a103f602f2837d968fd038df3ca17ae0c76.pdf.


22 Fisher D. IPDMETAN: Stata module for performing two-stage IPD meta-analysis. 2014.
32 van Blitterswijk M, DeJesus-Hernandez M, Niemantsverdriet E, et al. Association between repeat sizes and clinical and pathological characteristics in carriers of C9ORF72 repeat


Table 1 – Baseline demographics of C9orf72-tested ALS cases by country

<table>
<thead>
<tr>
<th>Variable</th>
<th>Belgium n = 482</th>
<th>Ireland n = 645</th>
<th>Italy n = 897</th>
<th>The Netherlands n = 2153</th>
<th>United Kingdom n = 929</th>
<th>P (Chi²)</th>
<th>Combined N = 5106</th>
</tr>
</thead>
<tbody>
<tr>
<td>Included after missing values removed Sex</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>180 (37.3%)</td>
<td>266 (41.6%)</td>
<td>411 (47.4%)</td>
<td>844 (41.4%)</td>
<td>352 (38.9%)</td>
<td></td>
<td>2053 (41.7%)</td>
</tr>
<tr>
<td>Male</td>
<td>297 (62.3%)</td>
<td>374 (58.4%)</td>
<td>456 (52.6%)</td>
<td>1193 (58.6%)</td>
<td>552 &lt;0.001</td>
<td></td>
<td>2872 (58.3%)</td>
</tr>
<tr>
<td>Age of Onset</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Median</td>
<td>61.4</td>
<td>63.0</td>
<td>66.8</td>
<td>63.0</td>
<td>61.3</td>
<td></td>
<td>63.1</td>
</tr>
<tr>
<td>Diagnostic Delay</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Short</td>
<td>161 (33.8%)</td>
<td>193 (30.2%)</td>
<td>285 (32.9%)</td>
<td>702 (43.5%)</td>
<td>300 (33.2%)</td>
<td></td>
<td>1641 (33.3%)</td>
</tr>
<tr>
<td></td>
<td>(88.3%)</td>
<td>(88.3%)</td>
<td>(87.3%)</td>
<td>(87.3%)</td>
<td>(87.3%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medium</td>
<td>163 (34.2%)</td>
<td>211 (33.0%)</td>
<td>293 (33.8%)</td>
<td>683 (33.5%)</td>
<td>298 (33.0%)</td>
<td></td>
<td>1648 (33.5%)</td>
</tr>
<tr>
<td></td>
<td>(86.3%)</td>
<td>(86.3%)</td>
<td>(86.3%)</td>
<td>(86.3%)</td>
<td>(86.3%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Long</td>
<td>153 (32.1%)</td>
<td>236 (36.9%)</td>
<td>289 (33.3%)</td>
<td>652 (32%)</td>
<td>306 (33.8%)</td>
<td>0.559</td>
<td>1636 (33.2%)</td>
</tr>
<tr>
<td></td>
<td>(86.3%)</td>
<td>(86.3%)</td>
<td>(86.3%)</td>
<td>(86.3%)</td>
<td>(86.3%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Site of Onset</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Spinal</td>
<td>326 (68.3%)</td>
<td>437 (68.3%)</td>
<td>583 (67.2%)</td>
<td>1333 (65.4%)</td>
<td>610 (67.5%)</td>
<td></td>
<td>3289 (66.8%)</td>
</tr>
<tr>
<td></td>
<td>(86.3%)</td>
<td>(86.3%)</td>
<td>(86.3%)</td>
<td>(86.3%)</td>
<td>(86.3%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bulbar</td>
<td>151 (31.7%)</td>
<td>203 (31.7%)</td>
<td>284 (32.8%)</td>
<td>704 (34.6%)</td>
<td>294 (32.5%)</td>
<td>0.540</td>
<td>1636 (33.2%)</td>
</tr>
<tr>
<td></td>
<td>(86.3%)</td>
<td>(86.3%)</td>
<td>(86.3%)</td>
<td>(86.3%)</td>
<td>(86.3%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C9orf72</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Normal</td>
<td>392 (82.2%)</td>
<td>578 (90.3%)</td>
<td>805 (92.8%)</td>
<td>1861 (91.4%)</td>
<td>841 (93.0%)</td>
<td></td>
<td>4477 (90.9%)</td>
</tr>
<tr>
<td></td>
<td>(90.3%)</td>
<td>(90.3%)</td>
<td>(90.3%)</td>
<td>(90.3%)</td>
<td>(90.3%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Expanded</td>
<td>85 (17.8%)</td>
<td>62 (9.7%)</td>
<td>62 (7.2%)</td>
<td>176 (8.6%)</td>
<td>63 (7%)</td>
<td>&lt;0.001</td>
<td>448 (9.1%)</td>
</tr>
<tr>
<td></td>
<td>(9.7%)</td>
<td>(9.7%)</td>
<td>(9.7%)</td>
<td>(9.7%)</td>
<td>(9.7%)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 1 Legend:
Diagnostic delay is defined by three tertiles per country labeled “short”, “medium” and “long” diagnostic delay to allow for variation in diagnostic delay between countries.

³ Kruskal-Wallis test
IQR = inter-quartile range
Table 2. Age of onset and diagnostic delay for hybrid sex/site of onset / C9 variable

<table>
<thead>
<tr>
<th>Level</th>
<th>Age at onset</th>
<th>Diagnostic delay</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Median</td>
<td>Short</td>
</tr>
<tr>
<td></td>
<td>(IQR)</td>
<td></td>
</tr>
<tr>
<td>Spinal onset excluding C9orf72</td>
<td>62.3</td>
<td>965</td>
</tr>
<tr>
<td>expanded males</td>
<td>(54.0 – 69.7)</td>
<td>(30.8%)</td>
</tr>
<tr>
<td>All bulbar onset</td>
<td>65.0</td>
<td>611</td>
</tr>
<tr>
<td></td>
<td>(58.4 – 71.9)</td>
<td>(37.4%)</td>
</tr>
<tr>
<td>Male spinal onset C9orf72 only</td>
<td>59.3</td>
<td>65</td>
</tr>
<tr>
<td></td>
<td>(52.3 – 64.7)</td>
<td>(40.8%)</td>
</tr>
<tr>
<td>P value</td>
<td>0.0001†</td>
<td>&lt;0.001†</td>
</tr>
</tbody>
</table>

* Kwallis test
† Chi² test
Table 3 – Hazard ratios for El Escorial criteria after inclusion in final model

<table>
<thead>
<tr>
<th>El Escorial Category</th>
<th>HR</th>
<th>95% CI</th>
<th>Wald test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Suspected</td>
<td>0.86</td>
<td>0.68 – 1.08</td>
<td>0.199</td>
</tr>
<tr>
<td>Possible</td>
<td>1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>Probable – Lab supported</td>
<td>1.38</td>
<td>1.31 – 1.44</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Probable</td>
<td>1.49</td>
<td>1.39 – 1.60</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Definite</td>
<td>2.09</td>
<td>1.99 – 2.21</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Sex/Site of onset/C9orf72

<table>
<thead>
<tr>
<th></th>
<th>HR</th>
<th>95% CI</th>
<th>Wald test</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spinal onset excluding male C9orf72 expanded cases</td>
<td>1</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td>All bulbar onset cases</td>
<td>1.33</td>
<td>1.21 – 1.45</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Male C9orf72 expanded cases only</td>
<td>1.57</td>
<td>1.26 – 1.96</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Table 3 Legend:

Hazard ratios for each of the El Escorial criteria from a Royston Parmar model on the hazard scale with 3 degrees of freedom and including age of onset (time varying), diagnostic delay, site of onset, country and sex-site-C9 as a hybridized variable with variance-covariance matrix allowed to pool by country. Note that Belgium was omitted as the El-Escorial criteria was not available, the UK data included only Probable and Definite category ALS, whilst Ireland does not use the “Probable lab supported” category as shown in table 1. Nevertheless, hazard ratios are in line with expectations showing a gradually increasing hazard with increasing category severity.
Table 4 – Summary of previous analyses of survival by C9orf72 status

<table>
<thead>
<tr>
<th>Study</th>
<th>Population</th>
<th>C9orf72</th>
<th>C9orf72</th>
<th>Median survival</th>
<th>Median age at onset</th>
<th>HR (CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Byrne et al</td>
<td>Ireland</td>
<td>170</td>
<td>21</td>
<td>-6 months</td>
<td>-3.2 yrs</td>
<td>1.9</td>
</tr>
<tr>
<td>Van Rheenen et al</td>
<td>The Netherlands</td>
<td>1422</td>
<td>78</td>
<td>-2.5 months</td>
<td>-2.6 yrs</td>
<td>1.46</td>
</tr>
<tr>
<td>Sabatelli et al</td>
<td>Italy &amp; Sardinia</td>
<td>1688</td>
<td>69</td>
<td>-1 yr</td>
<td>-3.8 yrs</td>
<td>1.79</td>
</tr>
<tr>
<td>Borghero et al</td>
<td>Sardinia</td>
<td>375</td>
<td>51</td>
<td>-1.5 yrs ‡‡</td>
<td>-0.9 yrs</td>
<td>na</td>
</tr>
<tr>
<td>Debray et al</td>
<td>Belgium</td>
<td>513</td>
<td>77</td>
<td>fALS -38.3</td>
<td>fALS -5.9 yrs</td>
<td>fALS 2.5</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>months</td>
<td>sALS -0.3 yrs</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>sALS -5.8 months</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>García-Redondo et al</td>
<td>Spanish</td>
<td>936</td>
<td>67</td>
<td>-12 months</td>
<td>-2.6 yrs ‡‡‡</td>
<td>na</td>
</tr>
<tr>
<td>Irwin et al</td>
<td>United States</td>
<td>69</td>
<td>64</td>
<td>-6 months</td>
<td>-3.0 yrs ‡‡‡</td>
<td>na</td>
</tr>
</tbody>
</table>

‡ Negative figures imply C9orf72 expanded survive for shorter time, or are younger at onset than C9orf72 normal cases
‡‡ Calculate as median survival in C9orf72 expanded group – median survival in overall cohort median
‡‡‡ Calculated from mean data instead of median
‡‡‡‡ Mixed ALS & FTD cases
fALS = familial ALS ; sALS = sporadic ALS
Figure 1 — Predicted survival by sex and \textit{C9orf72} status after multivariate Royston-Parmar regression including interaction terms

Figure 1 Legend: C9 Normal = group not carrying the C9orf72 expansion; C9 Exp. = group carrying the C9orf72 expansion present. Shaded areas represent 95% confidence intervals.

Predicted survival curves for interaction models between gender and \textit{C9orf72} status (upper), and site of onset and \textit{C9orf72} status (lower) after multivariate regression using a Royston Parmar model on the hazard scale (3 d.f.), correcting for age of onset (time varying), diagnostic delay group (time varying), site of onset, country and using a variance-covariance matrix clustered by country. The upper graph shows a wider spread by \textit{C9orf72} status in males compared to females, while the lower shows a wider spread in spinal onset cases vs bulbar onset cases – however hazard ratios for these interactions were not significant.
Figure 2 - Predicted survival function for male spinal onset \textit{C9orf72} expanded patients

Figure 2 legend: C9 exp. = group carrying the C9orf72 expansion. Shaded areas represent 95% confidence intervals.
Survival curves show three subgroups of patients categorized by sex, site of onset and \textit{C9orf72} status. Survival curves for male spinal onset patients with the \textit{C9orf72} repeat expansion are markedly worse than other spinal onset patients and are in fact inseparable from bulbar onset patients. Median predicted survival in the three groups were: Spinal excluding \textit{C9orf72} expanded males 2.77 (95%CI 2.67 – 2.87); bulbar onset 2.38 (95% CI 2.33 – 2.42); spinal onset males with \textit{C9orf72} repeat expansion 2.29 (95%CI 2.15 – 2.49).
Figure 3 - Individual Patient Data meta-analysis of the hazard ratio of male spinal onset ALS patients carrying the \textit{C9orf72} repeat expansion

Figure 3 legend: C9orf72exp. = group carrying the C9orf72 expansion.

IPD meta-analysis of \textit{C9orf72} repeat expansion in male spinal onset ALS patients versus spinal onset \textit{C9orf72} normal patients pooled by country and analysed using a Royston-Parmar flexible parametric model with 3 degrees of freedom on the hazard scale correcting for age at onset (time varying), site of onset and diagnostic delay, based on the 3 level categorical breakdown of sex, site, and \textit{C9orf72} status described in Suppl. Info. 2.